<DOC>
	<DOCNO>NCT01213966</DOCNO>
	<brief_summary>A Phase IIa Exploratory , Open label , Single Dose Regimen , Multiple Dose Testing Clinical Study Assess Preliminary Efficacy , Tolerability Pharmacokinetics OZ439 adult patient acute , uncomplicated Plasmodium falciparum vivax malaria mono-infection .</brief_summary>
	<brief_title>Efficacy , Tolerability , PK OZ439 Adults With Acute , Uncomplicated P.Falciparum Vivax Malaria Mono-infection</brief_title>
	<detailed_description>This exploratory Phase IIa study aim investigate preliminary efficacy term parasite reduction clearance malaria patient , tolerability OZ439 administer single dose regimen 3 different dos parallel cohort patient either acute uncomplicated Plasmodium falciparum Plasmodium vivax malaria mono-infection ( 10 patient per plasmodium specie per dose level ) . Treatment OZ439 give single dose Day 0 , start first cohort dose 800 mg . Established antimalarial therapy give late 36 hour post dose . The primary endpoint derive parasite reduction rate ( PRR ) 24 hour study drug administration . A review individual study cohort ( dose/species ) conduct Principal Investigator Sponsor decision reach whether dose next cohort increase decrease ( within 200mg-1600mg range ) . This decision base parasite reduction rate first 24 hour follow administration OZ439 , tolerability exposure .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Vivax</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<criteria>1 . Male female patient age 18 60 year , inclusive 2 . Body weight 40 kg 90 kg inclusive 3 . Presence monoinfection P. falciparum P. vivax confirm : Fever , define axillary temperature ≥ 37.5°C oral/rectal/tympanic temperature ≥ 38°C , history fever previous 24 hour ( history fever must document ) , Microscopically confirm parasite infection , 5,000 50,000 asexual parasite count/µl blood 4 . Written informed consent , accordance local practice , provide patient . If patient unable write , witness consent permit accord local ethical consideration 5 . Ability swallow oral medication 6 . Ability willingness participate access health facility 7 . Agree minimum 4 day hospitalisation drug administration pharmacokinetic sample 1 . Patients sign symptom severe/complicated malaria require parenteral treatment accord World Health Organisation Criteria 2010 ( Attachment 2 ) 2 . Mixed Plasmodium infection 3 . Severe vomiting , define three time 24 hour prior inclusion study inability tolerate oral treatment , severe diarrhoea define 3 watery stool per day 4 . Presence serious chronic clinical condition require hospitalisation . 5 . Severe malnutrition ( define weightforheight 3 standard deviation less 70 % median NCHS/WHO normalise reference value ) . 6 . Known history evidence clinically significant disorder cardiovascular ( include arrhythmia , QTc interval great equal 450 msec ) , respiratory ( include active tuberculosis ) , history jaundice , hepatic , renal , gastrointestinal , immunological ( include active HIVAIDS ) , neurological ( include auditory ) , endocrine , infectious , malignancy , psychiatric , history convulsion abnormality ( include head trauma ) . 7 . Known history hypersensitivity , allergic adverse reaction artemisinin contain compound mefloquine drug national guideline P. vivax . 8 . Known active Hepatitis A IgM ( HAVIgM ) , Hepatitis B surface antigen ( HBsAg ) Hepatitis C antibody ( HCV Ab ) . 9 . Have receive antimalarial treatment precede 14 day , determine history screen test . 10 . Have receive antibacterial know antimalarial activity precede 14 day . 11 . Have receive investigational drug within past 4 week . 12 . Liver function test ( ASAT/ALAT level ) 2 x ULN 13 . Hb level 10 g/dL . 14 . Bilirubin level great 40 µmol/L . 15 . Serum creatinine level 2 time upper limit normal range absence dehydration . In case important dehydration creatinine low 2X ULN oral/parenteral rehydration . 16 . Female patient must neither pregnant ( demonstrated negative serum pregnancy test ) lactating , must willing take measure become pregnant study period safety followup period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Acute uncomplicated Plasmodium Falciparum malaria</keyword>
	<keyword>Blood stage Plasmodium Vivax malaria</keyword>
</DOC>